{"id":1621,"date":"2025-05-05T16:05:24","date_gmt":"2025-05-05T10:35:24","guid":{"rendered":"https:\/\/wizreads.wizako.com\/gmat-gre-sat-reading-comprehension-practice-articles-blog\/?p=1621"},"modified":"2025-05-05T16:31:08","modified_gmt":"2025-05-05T11:01:08","slug":"vitanova-promises-unfulfilled-gmat-gre-rc-practice","status":"publish","type":"post","link":"https:\/\/wizreads.wizako.com\/gmat-gre-sat-reading-comprehension-practice-articles-blog\/business-economy\/vitanova-promises-unfulfilled-gmat-gre-rc-practice\/","title":{"rendered":"Vitanova – Promises Unfulfilled | GMAT GRE RC Practice"},"content":{"rendered":"\n

Is biotech\u2019s culture of “fake it till you make it” a gateway to innovation or a dangerous precedent? These challenging passages examine how startup ethics, regulatory gaps, and investor practices collide in the high-stakes world of biomedical technology. Let\u2019s navigate the tension between rapid innovation and patient safety, requiring you to distinguish between superficial industry changes and meaningful reforms in the wake of high-profile scandals.<\/p>\n\n\n\n

Read these challenging GMAT and medium difficulty GRE passage(s) in Business, Economy, and Governance<\/a> and answer the question(s) that follows. You can choose the GMAT style Reading Passage and the question or the GRE RC variant and answer the GRE-style question. Even better, you could solve both.<\/p>\n\n\n\n

\n
\n
\n
GMAT RC Practice<\/a><\/div>\n<\/div>\n<\/div>\n\n\n\n
\n
\n
GRE Reading Passage<\/a><\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n

Hard GMAT RC Passage | ~200 words<\/h2>\n\n\n\n

The rapid downfall of medical technology startup Vitanova has catalyzed substantive discourse regarding investment practices within the innovation ecosystem. Despite initial valuations exceeding $9 billion and claims of revolutionary diagnostic capabilities, Vitanova’s technology proved fundamentally nonviable, precipitating criminal charges against its founder for deliberately misleading investors. Industry observers remain divided regarding whether this case represents an isolated incident or symptomatic evidence of systemic deficiencies. Professor Marcus Kalinowski, who initially questioned Vitanova’s methodologies, asserts that contemporary medical technology ventures continue employing similar questionable practices, operating in what he terms “stealth mode” while securing substantial funding without providing empirical validation of their technologies.<\/p>\n\n\n\n

Research published in the Journal of Biomedical Innovation corroborates this assessment, revealing that among eighteen highly-valued medical technology companies, over half lacked substantive peer-reviewed publications supporting their claims. Regulatory shortcomings further exacerbate these concerns, as diagnostic technologies frequently occupy regulatory grey areas that permit market entry with minimal oversight. Kalinowski emphasizes the particularly concerning nature of healthcare innovations compared to consumer technologies, noting the direct implications for patient outcomes. While increased scrutiny has emerged post-Vitanova, multiple experts contend that fundamental structural reforms remain unrealized, suggesting that the innovation ecosystem has yet to undergo comprehensive recalibration despite this cautionary example.<\/p>\n\n\n\n

GMAT RC Question Type: Extrapolation | Question Difficulty: High<\/h3>\n\n\n\n

Based on the passage, all of the following hypothetical situations demonstrate the problems highlighted in the passage EXCEPT:<\/strong><\/p>\n\n\n\n

    \n
  1. A biotech startup secures $500 million in funding based on preliminary lab results without publishing its methodology in peer-reviewed journals<\/li>\n\n\n\n
  2. A diagnostic technology company operates in regulatory ambiguity by classifying its product as a “wellness device” rather than a medical instrument<\/li>\n\n\n\n
  3. A medical technology incubator requires its portfolio companies to submit quarterly progress reports with data before receiving additional funding<\/li>\n\n\n\n
  4. Venture capitalists continue to prioritize rapid growth potential over verified scientific validation when investing in healthcare startups<\/li>\n\n\n\n
  5. A medical AI company raises significant capital while keeping its algorithms and validation methods confidential from potential competitors<\/li>\n<\/ol>\n\n\n\n
    \n GMAT RC Question Answer & Explanation ▼<\/span><\/strong><\/summary>\n

    The passage identifies several problems in the medical technology space: operating in “stealth mode” without transparency (options 1 and 5), insufficient regulatory oversight (option B), prioritizing growth over validation (option 4), and lack of empirical validation before funding. Option (C) describes a medical technology incubator requiring empirical data and regular reporting before additional funding – this represents a solution addressing the transparency and validation issues highlighted in the passage, not a demonstration of the problems themselves. \n

    \nCorrect Answer: Choice (C)<\/strong><\/p>\n\n<\/details>\n\n\n